Cart
sales@molnova.com
Befotertinib
CAS No. 1835667-63-4
Befotertinib( D-0316 )
Catalog No. M28217 CAS No. 1835667-63-4
Befotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 235 | In Stock |
|
| 5MG | 187 | In Stock |
|
| 10MG | 297 | In Stock |
|
| 25MG | 525 | In Stock |
|
| 50MG | 732 | In Stock |
|
| 100MG | 1004 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBefotertinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionBefotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
-
DescriptionBefotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
-
In Vitro——
-
In Vivo——
-
SynonymsD-0316
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorCDK2|CDK5
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1835667-63-4
-
Formula Weight567.61
-
Molecular FormulaC29H32F3N7O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (88.09 mM)
-
SMILESC=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(CC(F)(F)F)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(C)CCN(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ka?mierczak A, et al. A novel mechanism of non-Aβ component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5). Neurochem Int. 2011;58(2):206-214.
molnova catalog
related products
-
Pelitinib
A potent, selective, orally active, irreversible inhibitor of EGFR with IC50 of 80 nM.
-
GSK-LSD1 dihydrochlo...
GSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).
-
Anlotinib
Anlotinib (AL-3818) is a novel multi-target tyrosine kinase that primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret.
